drugset / Trial / NCT01262391

Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

NCT01262391

Phase 1 Completed 42 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This single-dose study will investigate how well solifenacin suspension is taken up, how long it stays in the body and how well it will be tolerated in children and adolescents aged 5-17 years with symptoms of overactive bladder.

Timeline

Start
2010-10-20
Primary completion
2011-08-14
Completion
2011-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule 2.5 mg Oral
Subject Solifenacin Small molecule 5 mg Oral
Subject Solifenacin Small molecule 10 mg Oral

Indications